Article
Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.
Blood - 15 Jan 2026
Popescu Bogdan, Jones Matthew F, Piao Madison, Tran Elaine, Koh Andrew, Lomeli Isabelle, Peretz Cheryl A C, Murad Natalia, Abelson Sydney, Morales Carolina, Rivera Jose M, Batingana Alexa Rane, D'Souza Jeevitha, Pikman Yana, Cheng Michael L, Logan Aaron C, Huang Benjamin J, Stieglitz Elliot, Smith Catherine C
Abstract excerpt
ABSTRACT: Aberrant activation of RAS/MAPK signaling limits the clinical efficacy of several targeted therapies in acute myeloid leukemia (AML). In FMS-like tyrosine kinase-3 (FLT3)-mutant AML, the selection of clones harboring heterogeneous RAS mutations drives resistance to FLT3 inhibitors (FLT3i). RAS activation is also associated with resistance to other AML targeted therapies, such as the B-cell lymphoma 2...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.